Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,201 across all filing types
Latest filing 2025-12-24 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
上海东方华银律师事务所关于灵康药业集团股份有限公司2025年第三次临时股东会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening and procedures of the 2025 third extraordinary general meeting (临时股东会) of Lingkang Pharmaceutical Group Co., Ltd. It details the legality of the meeting's notice, attendance, voting procedures, and resolutions passed. The document does not contain financial statements or results but focuses on the legal compliance and validity of the shareholder meeting and its resolutions. This type of document is typically associated with announcements or confirmations related to shareholder meetings, specifically the declaration of voting results or voting rights announcements. Given the detailed voting results and legal opinion on the meeting's validity, the document fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 2615 characters, which is relatively short but contains substantive content about voting results, not just an announcement of a report publication or a regulatory filing. Therefore, the classification is DVA with high confidence.
2025-12-24 Chinese
2025年第三次临时股东会会议资料
AGM Information Classification · 95% confidence The document is titled as materials for the "2025 Third Extraordinary General Meeting of Shareholders" of Lingkang Pharmaceutical Group Co., Ltd. It includes the meeting agenda, voting procedures, and a key proposal regarding the appointment of the 2025 audit firm. The content is focused on the meeting logistics and the proposal for appointing the auditor, not the audit report itself. The document is about the meeting materials provided to shareholders for the extraordinary general meeting, which fits the definition of AGM Information (AGM-R). The document length is 4777 characters, which is consistent with a meeting material document rather than a full report. Therefore, the classification is AGM Information (AGM-R).
2025-12-18 Chinese
关于不向下修正“灵康转债”转股价格的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from the board of Lingkang Pharmaceutical Group Co., Ltd. regarding the decision not to adjust downward the conversion price of its convertible bonds ('Lingkang Convertible Bonds'). It details the bond issuance, previous adjustments to the conversion price, the triggering of the downward adjustment clause, and the board's resolution not to exercise the right to lower the conversion price at this time. The document is regulatory in nature, providing an update on convertible bond terms and board decisions, but it does not contain financial statements or detailed financial analysis. It is not a full financial report, earnings release, or management discussion. It is a formal announcement related to capital structure and bond terms, specifically about convertible bond price adjustment rights. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is short (1980 characters), but it is substantive and not merely a report publication announcement or certification. Hence, CAP is the best fit with high confidence.
2025-12-09 Chinese
关于聘任2025年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the appointment of the audit firm for the fiscal year 2025. It details the change of the company's auditor, the qualifications and background of the new auditor, the reasons for the change, and the approval process by the board and audit committee. It does not contain any financial statements or audit reports themselves, but rather the announcement of the auditor appointment. The document length is 3420 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document fits best into the category of Audit Report / Information (AR) as it relates to audit matters but is not a full annual report or audit report itself. However, since it is specifically about the appointment of the audit firm and not the audit report, it is best classified as an Audit Report / Information (AR) rather than Annual Report (10-K) or Report Publication Announcement (RPA). FY 2025
2025-12-02 Chinese
第五届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board of directors meeting, including the appointment of an audit firm and the proposal to convene a shareholders meeting. It details the meeting date, attendance, voting results, and procedural compliance. There is no financial data or report content, only decisions and procedural information. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board. The document is short (935 characters) and does not contain an actual report or financial statements, so it is not an Annual Report or Audit Report. It is not a report publication announcement since it contains substantive meeting resolution content rather than just a notice of report availability.
2025-12-02 Chinese
关于“灵康转债”预计满足转股价格修正条件的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the expected triggering of convertible bond conversion price adjustment conditions. It details the bond issuance, previous price adjustments, the conditions under which the conversion price may be adjusted downward, and the company's obligations to disclose such information. The document is a regulatory disclosure about convertible bond price adjustments and related corporate actions, not a full financial report or earnings release. It is an announcement of a capital/financing update related to convertible bonds and their conversion price adjustments. The document length is under 5,000 characters and it is a specific announcement about financing terms and conditions, fitting the Capital/Financing Update category rather than a full report or regulatory filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-12-02 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.